Aroa Biosurgery Ltd (AU:ARX) has released an update.
Aroa Biosurgery Ltd has disclosed a change in the indirect interest of Director Brian Ward, with an acquisition of 961,255 Performance Rights, as per a shareholder-approved issuance at the company’s Annual General Meeting on 23 July 2024. The update, which has been reported to the ASX under listing rule 3.19A.2, shows no disposal of securities and maintains Mr. Ward’s substantial holding in the company, including over 33 million fully paid ordinary shares and various tranches of options.
For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.
